Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease
|
|
- Lewis Sullivan
- 5 years ago
- Views:
Transcription
1 CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease
2 Disclosures Research contracts: AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, FDA, Janssen, Novartis, GSK, Medtronic Foundation, Pfizer, The Medicines Company, FDA, NIH Consulting/Honoraria: AstraZeneca, Bayer, BMS, Boston Scientific, GSK, Pfizer, Lilly, Daiichi Sankyo, Novartis, Boehringer Ingelheim, Medtronic, Medtronic Foundation, Rho For full listing see
3 Anticoagulation to prevent thrombotic coronary artery disease events: a paradigm shift?
4 Secondary Prevention with Warfarin and ASA vs ASA alone after ACS 10 trials; n = 5938 Rate ratio (95% CI) Death 0.96 ( ) MI 0.56 ( ) Ischemic stroke 0.46 ( ) Major bleeding event 2.48 ( ) Minor bleeding event 2.65 ( ) Warfarin + Rate ratio ASA better ASA better Rothberg MB et al. Ann Intern Med 2005;143;
5 Warfarin and ASA vs ASA alone after ACS 10 trials; n = 5938 Rothberg MB et al. Ann Intern Med 2005;143;
6 Do not add aspirin to oral anticoagulation without a clear indication
7 Bleeding According to Antiplatelet Rx W none ASA ASA + clopi D 150 D 110 Series of no, single, and dual antiplatelet therapy HRs adjusted for age, gender, warfarin experience, SBP, CAD, HF, hypertension, diabetes, TIA, CrCl and statin use. Circulation. published online December 27, 2012
8 ASPECT-2 and WARIS II Trials: OAC vs ASA vs Both ASPECT-2 WARIS II Death, MI, stroke Death, MI, stroke Advances in pharmacogenomics will ultimately permit patient-specific antithrombotic therapy for patients with acute coronary syndromes and other thrombotic disorders. Becker RC WARIS II editorial Lancet 2002; 360: N Engl J Med 2002;347:
9 DAPT Guidelines DAPT for at least one year following ACS DAPT for at least 6 months following DES for stable CAD Can shorten therapy based on high bleeding risk
10 Rivaroxaban in Coronary Disease Acute coronary syndromes»atlas trials Patients treated with stents»gemini Patients with AF and stents»pioneer (and RE-DUAL) Patients with AF and coronary disease»rocket Patients with stable vascular disease»compass
11 Estimated Cumulative Incidence (%) PRIMARY EFFICACY ENDPOINT: CV Death / MI / Stroke Placebo 2 Yr KM Estimate 10.7% 8.9% Rivaroxaban (both doses) HR 0.84 ( ) mitt p = ITT p = ARR 1.8% NNT = 56 No. at Risk Placebo Rivaroxaban Months After Randomization HR and 95% confidence interval estimates from Cox model stratified by thienopyridine use are provided per mitt approach; Stratified log-rank p-values are provided for both mitt and ITT approaches.
12 Estimated Cumulative incidence (%) 12% CV Death / MI / Stroke HR 0.85 mitt p=0.039 ITT p=0.011 EFFICACY ENDPOINTS: Very Low Dose 2.5 mg BID Patients Treated with ASA + Thienopyridine Cardiovascular Death Placebo HR 0.62 Placebo HR % 9.0% 5% 5% mitt p<0.001 ITT p< % mitt p<0.001 ITT p<0.001 All Cause Death Placebo 4.5% 2.5% 2.7% Rivaroxaban 2.5 mg BID Months Months Months 0 24 Rivaroxaban 2.5 mg BID NNT = 71 NNT = 59 Rivaroxaban 2.5 mg BID NNT =
13 Percent (%) TREATMENT-EMERGENT FATAL BLEEDS AND ICH p=ns for Riva vs Placebo p=ns for Riva 5 vs Placebo p=ns for Riva 2.5 vs Placebo p=0.044 for Riva 2.5 vs 5 p=0.009 for Riva vs Placebo p= Riva 5 vs Placebo P=0.037 for Riva 2.5 vs Placebo p=0.44 for Riva 2.5 vs 5 Placebo 2.5 mg Rivaroxaban 5.0 mg Rivaroxaban n=9 n=6 n= n=5 n=14 n=18 p=ns for all comparisons Fatal ICH Fatal ICH 0.2 n=4 n=5 n=8
14 Stent Thrombosis with NOAC Plus DAPT vs DAPT Alone Definite/prob 35% Definite/prob/poss 31% Gibson CM et al. J Am Coll Cardiol. 2013;62:
15 Stent Thrombosis with NOAC Plus DAPT vs DAPT Alone after ACS Reported stent thrombosis (%) Trial f/u (m) n NOAC Placebo RR 95% CI) NNT APPRAISE-2 8 7, ( ) * 250 ATLAS , ( ) ** Both doses * p=0.15 ** p=0.02 Verheugt FWA. Eur Heart J 2013;34:
16 For patients with ACS, after several days, on clopidogrel, randomized to rivaroxaban (2.5 bid) vs aspirin
17 Exploratory Individual Ischemic Endpoints Aspirin (N=1518) Rivaroxaban (N=1519) HR (95% CI) P Value CV death, MI, stroke, or definite stent thrombosis 72 (4.7%) 76 (5.0%) 1.06 ( ) 0.73 MI 49 (3.2%) 56 (3.7%) 1.15 ( ) 0.49 Stroke 12 (0.8%) 7 (0.5%) 0.58 ( ) 0.25 All stent thrombosis 16 (1.1%) 17 (1.1%) 1.06 ( ) 0.86
18 Stenting in patients with AF Prevent stent thrombosis Prevent stroke DAPT + OAC Causes lots of bleeding
19 Triple therapy perpectives North American Perspective 2016 ESC DAPT Guidelines Circ Cardiovasc Interv. 2016;9:e Valgimigli M, et al. Eur Heart J 2017;0:1-48.
20 Dose of Rivaroxaban Varies in ACS & Atrial Fibrillation Patients ACS/ Stenting Stent + Afib Atrial Fibrillation DAPT mg BID Riva Riva 20 mg QD 4 Fold Difference in Riva Dose Between ACS and AF 1. Schmitt J et al Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009;30: Gibson et al. AHA 2016
21 TIMI Major, TIMI Minor, or Bleeding Requiring Medical Attention (%) Kaplan-Meier Estimates of First Occurrence of Clinically Significant Bleeding Events 26.7% VKA VKA + DAPT + DAPT Riva + DAPT p< p< % 16.8% Riva + P2Y 12 v. VKA + DAPT HR=0.59 (95% CI: ) p < ARR=9.9 NNT=11 Riva + P2Y 12 HR = 0.63 (95% CI ) HR ARR = 0.59 = (95% 8.7 Riva + CI DAPT ) v. VKA + DAPT ARR NNT = 9.9 = 12HR=0.63 (95% CI: ) NNT = 11 p < ARR=8.7 NNT=12 Gibson et al. AHA 2016 No. at risk VKA Riva + DAPT P2Y 12 VKA Riva + DAPT VKA + DAPT Days Treatment-emergent period: period starting after the first study drug administration following randomization and ending 2 days after stop of study drug. Clinically significant bleeding is the composite of TIMI major, TIMI minor, and BRMA. Hazard ratios as compared to the VKA group are based on the (stratified, only for Overall, 2.5 mg BID/15 mg QD comparing VKA) Cox proportional hazards model. Log-Rank P-values as compared to VKA group are based on the (stratified, only for Overall, 2.5 mg BID/15 mg QD comparing VKA) two-sided log rank test.
22 Major Adverse Cardiac Events All Strata Kaplan-Meier Estimates Hazard Ratio (95% CI) Overall Riva + P2Y 12 (N=694) Riva + DAPT (N=704) VKA + DAPT (N=695) Riva + P2Y 12 vs. VKA + DAPT Riva + DAPT vs. VKA + DAPT Adverse CV Event 41 (6.5%) 36 (5.6%) 36 (6.0%) 1.08 ( ) p= ( ) p=0.765 CV Death 15 (2.4%) 14 (2.2%) 11 (1.9%) 1.29 ( ) p= ( ) p=0.664 MI 19 (3.0%) 17 (2.7%) 21 (3.5%) 0.86 ( ) p= ( ) p=0.374 Stroke 8 (1.3%) 10 (1.5%) 7 (1.2%) 1.07 ( ) p= ( ) p=0.530 Stent Thrombosis 5 (0.8%) 6 (0.9%) 4 (0.7%) 1.20 ( ) p= ( ) p=0.574 Adverse CV Events + Stent Thrombosis 41 (6.5%) 36 (5.6%) 36 (6.0%) 1.08 ( ) P= ( ) p=0.765 Gibson et al. AHA 2016 Treatment-emergent period: period starting after the first study drug administration following randomization and ending 2 days after stop of study drug. A subject could have more than component event. n = number of subjects with events, N = number of subjects at risk, % = KM estimate at the end of study. Hazard ratios as compared to VKA group are based on the (stratified, only for Overall, 2.5 mg BID/15 mg QD comparing VKA) Cox proportional hazards model. Log-Rank p-values as compared to VKA group are based on the (stratified, only for Overall 2.5 mg BID/15 mg QD comparing VKA) two-sided log rank test. CI = confidence interval, DAPT = dual antiplatelet therapy, HR = hazard ratio, VKA = vitamin K antagonist 6 Subjects were excluded from all efficacy analyses because of violations in Good Clinical Practice guidelines.
23 Probability of event (%) Primary Endpoint: Time to first ISTH major or clinically relevant non-major bleeding event HR: 0.52 (95% CI: ) Non-inferiority P< P< Warfarin triple therapy HR: 0.72 (95% CI: ) Non-inferiority P< P=0.002 Warfarin triple therapy Dabigatran 150 mg dual therapy 15 Dabigatran 110 mg dual therapy Time to first event (days) Time to first event (days) Full analysis set presented. HRs and Wald CIs from Cox proportional-hazard model. For the dabigatran 110 mg vs warfarin comparison, the model is stratified by age, non-elderly vs elderly (<70 or 70 in Japan and <80 or 80 years old elsewhere). For the dabigatran 150 mg vs warfarin comparison, an unstratified model is used, elderly patients outside the USA are excluded. Noninferiority P value is one sided (alpha=0.025). Wald two-sided P value from (stratified) Cox proportional-hazard model (alpha=0.05)
24 Additional individual thromboembolic endpoints Dabi 110 mg dual therapy (n=981) n (%) Warfarin triple therapy (n=981) n (%) D110 DT vs warfarin TT Dabi 150 Warfarin D150 DT vs warfarin TT mg dual triple therapy therapy HR (95% CI) P value (n=763) (n=764) HR (95% CI) P value n (%) n (%) All-cause death 55 (5.6) 48 (4.9) 1.12 ( ) (3.9) 35 (4.6) 0.83 ( ) 0.44 Stroke 17 (1.7) 13 (1.3) 1.30 ( ) (1.2) 8 (1.0) 1.09 ( ) 0.85 Unplanned revascularization 76 (7.7) 69 (7.0) 1.09 ( ) (6.7) 52 (6.8) 0.96 ( ) 0.83 MI 44 (4.5) 29 (3.0) 1.51 ( ) (3.4) 22 (2.9) 1.16 ( ) 0.61 Stent thrombosis 15 (1.5) 8 (0.8) 1.86 ( ) (0.9) 7 (0.9) 0.99 ( ) 0.98 Results presented are times to event. Stent thrombosis is time to definite stent thrombosis
25 Triple vs Dual Therapy in AF and PCI: Meta-analysis Piccini JP, Jones WS. N Engl J Med 2017;377:
26 Eikelboom JW et al. N Engl J Med 2017; 377:
27 Primary: CV death, stroke, MI Outcome R + A N=9,152 A N=9,126 Rivaroxaban + aspirin vs. aspirin N (%) N (%) HR (95% CI) p CV death, stroke, MI 379 (4.1%) 496 (5.4%) 0.76 ( ) <
28 Components of primary outcome R + A N=9,152 Aspirin N=9,126 Riva + aspirin vs. aspirin N (%) N (%) HR (95% CI) p CV death 160 (1.7) 203 (2.2) 0.78 ( ) 0.02 Stroke 83 (0.9) 142 (1.6) 0.58 ( ) < MI 178 (1.9) 205 (2.2) 0.86 ( ) 0.14 Eikelboom JW et al. N Engl J Med 2017; 377: October 4, 2017
29 Myocardial infarction Event R + A N=9,152 N (%) Aspirin N=9,126 N (%) HR (95% CI) Riva + aspirin vs. aspirin p MI or SCD 247 (2.7%) 289 (3.2%) 0.85 ( ) 0.06 MI, SCD, or cardiac arrest 273 (3.0%) 333 (3.6%) 0.81 ( ) 0.01 MI, SCD, resus. Cardiac arrest, or unstable angina 277 (3.0%) 331 (3.6%) 0.83 ( ) 0.02 Eikelboom JW et al. N Engl J Med 2017; 377: October 4, 2017
30 Rivaroxaban + aspirin vs aspirin Net benefit Outcome Riva + aspirin N=9,152 Aspirin N=9,126 Rivaroxaban + aspirin vs. aspirin N % N % HR 95% CI P Primary + severe bleeds Eikelboom JW et al. N Engl J Med 2017; 377: October 4, 2017
31 COMPASS in context - Antithrombotics for 2 0 prevention CAPRIE Clopidogrel CHARISMA Clopidogrel + aspirin PEGASUS Ticagrelor 90 + aspirin PEGASUS Ticagrelor 60 + aspirin COMPASS Rivaroxaban + aspirin MACE 7% 7% 15% 16% 24% Death 2% 1% 0% 11% 18% Stroke - 21%* 18% 25% 42% MI - 6%* 19% 16% 14% M. Bleeds 27% -25%-62% -169% -132% -70% ICH 29% 4% -44% -33% -16% *Non-fatal. severe and moderate GUSTO, respectively October 4, 2017
32 COMPASS in context Lipid lowering (1mmol/L) BP Lowering (10mm Hg) ACE (HOPE) COMPASS Rivaroxaban+ aspirin MACE 21% 20% 22% 24% Death 9% 13% 16% 18% Stroke 15% 27% 32% 42% MI 24% 17% 20% 14% MALE % 46% HOPE Investigators. N Engl J Med 2000;342: Ettehad D, et al. Lancet 2016;387: CTT Collaboration. Lancet 2015;385: ; Collins R, et al. Lancet 2016;388: October 4, 2017
33 Summary Oral anticoagulation provides substantial protection against thrombotic vascular events Oral anticoagulation, especially when combined with antiplatelet therapy, has substantial bleeding risk Some oral anticoagulation (rivaroxaban 2.5 bid) has been shown to be the sweet spot where the antithrombotic benefit is greater than the bleeding risk, supported by the 18% RRR in mortality in COMPASS (and mortality reduction in ATLAS-2) For patients like those in COMPASS, there are important overall benefits of rivaroxaban 2.5 bid with aspirin which are likely to be cost effective The cost effectiveness of this therapy in practice will depend on patient risks of thrombotic and bleeding events
Antithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationChanging Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events
Changing Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events Deepak L. Bhatt, MD, MPH Executive Director Interventional Cardiovascular Programs Brigham and Women s Hospital
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationStudy design: multicenter, randomized, open-label trial following a PROBE design
Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationState of the Art in the ACS Atrial Fibrillation Overlap Syndrome
State of the Art in the ACS Atrial Fibrillation Overlap Syndrome C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationDr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου
Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Θεσσαλονίκη, 9/2/2018 Disclosures: None Primary efficacy outcome* (%/year) Antiplatelet Therapy
More informationTriple Therapy After PCI in AF: A Quagmire Soon to be Drained
Triple Therapy After PCI in AF: A Quagmire Soon to be Drained Freek W.A. Verheugt Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG) Amsterdam, Netherlands DISCLOSURES FOR FREEK W. A. VERHEUGT
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationDoes COMPASS Change Practice?
Does COMPASS Change Practice? C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division Chairman, PERFUSE Study Group Founder,
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationΣτεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές
4 ο ΠΑΝΕΛΛΗΝΙΟ ΑΡΡΥΘΜΙΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ 21-22 ΣΕΠΤΕΜΒΡΙΟΥ 2018 HILTON, ΑΘΗΝΑ Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές Ι. Κανακάκης MD, PhD Διευθυντής Αιμοδυναμικού Τμήματος
More informationNAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING
NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING Snehal H. Bhatt, Pharm.D., BCPS-AQ Cardiology, FASHP, AACC Associate Professor of Pharmacy Practice MCPHS
More informationRe- Setting our COMPASS for Secondary Prevention in Atherosclerotic Vascular Disease
Re- Setting our COMPASS for Secondary Prevention in Atherosclerotic Vascular Disease Robert C. Welsh, MD, FRCPC Professor of Medicine, University of Alberta Zone Clinical Department Head, Cardiac Sciences
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationByeong-Keuk Kim, M.D. Ph D. Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea
Byeong-Keuk Kim, M.D. Ph D Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea CASE, M/64 C.C; Recently aggravated chest discomfort for 3 days
More informationDisclosure Slide. Controversies in Anticoagulation. Presenter Disclosure Information. Challenges in Anticoagulation
1:15 2:15 PM Challenges in Anticoagulation SPEAKER Nasser Lakkis, MD, FACC, FSCAI Presenter Disclosure Information The following relationships exist related to this presentation: Nasser Lakkis, MD, FACC,
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationTriple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health
Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationΠροβληματισμοι στην χρηση αντιαιμοπεταλιακων στα οξέα ισχαιμικά σύνδρομα
Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΚΑΙ ΟΜΩΝΥΜΟ ΕΡΓΑΣΤΗΡΙΟ ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΑΘΗΝΩΝ ΙΠΠΟΚΡΑΤΕΙΟ ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΩΝ Διευθυντής: Καθηγητής ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Προβληματισμοι στην χρηση αντιαιμοπεταλιακων
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationA Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
More informationDays
Post ACS Care 2013 Clinical dilemmas Christopher Granger, MD Professor of Medicine Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic
More informationQuoi de neuf en cardio-gériatrie? Pr Olivier Hanon Hôpital Broca, Paris
Quoi de neuf en cardio-gériatrie? Pr Olivier Hanon Hôpital Broca, Paris Déclaration de relations professionnelles et liens d intérêt Novartis, Daiichi-Sankyo, Boehringer-Ingelheim, Bayer, BMS, Pfizer,
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationRobert C. Welsh, MD, FRCPC Professor of Medicine, University of Alberta Zone Clinical Department Head, Cardiac Sciences
Managing Atrial Fibrillation and ACS/PCI Applying New Evidence to Clinical Practice Dual Anti-Thrombotic Therapy in Acute Coronary Syndromes (ACS) and Afib + PCI/ACS Patients Robert C. Welsh, MD, FRCPC
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationThe Great debate: thrombocardiology post-compass
The Great debate: thrombocardiology post-compass Anticoagulation should replace antiplatelets in CAD prevention - CON Jean-Philippe COLLET Jean-philippe.collet@psl.aphp.fr Sorbonne Université_Action Study
More informationPaolo Gresele Dipartimento di Medicina Sezione di Medicina Interna e Cardiovascolare Università di Perugia
Anticoagulanti e mono-antiaggregazione: a chi, quali e per quanto tempo Paolo Gresele Dipartimento di Medicina Sezione di Medicina Interna e Cardiovascolare Università di Perugia Anticoagulazione: Bologna,
More informationThrombin Receptor Antagonists and Other New Oral Antiplatelets Drugs
Thrombin Receptor Antagonists and Other New Oral Antiplatelets Drugs David J. Moliterno, MD Professor and Chairman Department of Internal Medicine The University of Kentucky Linda and Jack Gill Heart Institute
More informationUpdate on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:
More information8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationOvercoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD
Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Disclosures Research contracts: AstraZeneca, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company,
More informationThe Korean Society of Cardiology COI Disclosure
The Korean Society of Cardiology COI Disclosure Name of First Author: Yongwhi Park The authors have no financial conflicts of interest to disclose concerning the presentation 2017 Annual Spring Scientific
More informationAnticoagulants and antiplatelet therapy in the older patient: Choosing wisely
Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely Rajiv Gulati, MD PhD Advances in Cardiac Arrhythmias & Great Innovations in Cardiology Torino, October 2015 2015 MFMER 3477310-1
More informationWHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France.
TAVI WITH ATRIAL FIBRILLATION: WHICH ANTITHROMBOTIC REGIMEN? G. MONTALESCOT (PARIS, FR) Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France www.action-cœur.org Dr. Montalescot
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationUPDATES FROM THE 2018 ANTIPLATELET GUIDELINES
UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 21st Annual Contemporary Therapeutic Issues in
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationAcute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT
Acute coronary syndromes A European viewpoint Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT Potential conflicts of interest In the past 2 years Felicita
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationΔΙΑΧΕΙΡΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΣΤΕΦΑΝΙΑΙΑ ΚΑΡΔΙΟΠΑΘΕΙΑ ΚΑΙ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ:ΚΙΝΔΥΝΟΙ ΚΑΙ ΟΦΕΛΗ ΔΙΠΛΗΣ ΚΑΙ ΤΡΙΠΛΗΣ ΘΕΡΑΠΕΙΑΣ
ΔΙΑΧΕΙΡΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΣΤΕΦΑΝΙΑΙΑ ΚΑΡΔΙΟΠΑΘΕΙΑ ΚΑΙ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ:ΚΙΝΔΥΝΟΙ ΚΑΙ ΟΦΕΛΗ ΔΙΠΛΗΣ ΚΑΙ ΤΡΙΠΛΗΣ ΘΕΡΑΠΕΙΑΣ Χρήστος Δ.Καλλιάνος Α Καρδιολογικό τμήμα και Ηλεκτροφυσιολογικό Εργαστήριο ΓΝΑ «Ο Ευαγγελισμός»
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationAntithrombotic Therapy for Long-Term Secondary Prevention Considerations for Long-Term DAPT
Antithrombotic Therapy for Long-Term Secondary Prevention Considerations for Long-Term DAPT Marc P. Bonaca, MD, MPH Vascular Section, Cardiovascular Division Investigator TIMI Study Group Brigham and Women
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationThe Myth of Class Effect Antithrombotics Christopher Cannon, MD
The Myth of Class Effect Antithrombotics Christopher Cannon, MD Cardiovascular Division Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Senior Investigator, TIMI Study
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationRazionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta
Razionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta Giuseppe Musumeci SC Cardiologia Ospedale Santa Croce e Carle Cuneo
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationSCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable?
SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable? tielle est 2 ré Totielle est interdite. Prof. Marco Roffi Hôpitaux Universitaires de Genève Research funding
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More informationIs the combination of antithrombotics and lowdose anticoagulants worthwhile in PAD The VOYAGER trial
Is the combination of antithrombotics and lowdose anticoagulants worthwhile in PAD The VOYAGER trial Thomas HW Stadlbauer Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationAF detection: What s new? Christopher B. Granger
AF detection: What s new? Christopher B. Granger Disclosures Research contracts: Apple, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Novartis, GSK, Medtronic Foundation, Pfizer,
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationPlatelet inhibition PLUS low-dose anticoagulation a new paradigm for all PAD patients?
Platelet inhibition PLUS low-dose anticoagulation a new paradigm for all PAD patients? Thomas HW Stadlbauer, MD Klinikum rechts der Isar, Technical University of Munich Disclosure Speaker name: Thomas
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationPAR-1 Antagonist: What Do Clinical Trials Teach Us?
Prevention of Atherothrombotic Events: What s the New Evidence? PAR-1 Antagonist: What Do Clinical Trials Teach Us? David A. Morrow, MD, MPH Director, Levine Cardiac Intensive Care Unit Senior Investigator,
More informationSecondary Stroke Prevention: A Precautionary Tale
Secondary Stroke Prevention: A Precautionary Tale Kirsten George-Phillips, BSP Clinical Practice Leader, AHS Clinical Pharmacist, AHS Owen Stroke Prevention Clinic Learning Objectives! Examine literature
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationAntiplatelet Therapy in Patients on Anticoagulation
Antiplatelet Therapy in Patients on Anticoagulation Ziad A Ali MD DPhil Cardiovascular Research Foundation Columbia University New York, Medical NY Center Cardiovascular Research Foundation Disclosure
More informationNew Study Presented at American Heart Association (AHA) Scientific Sessions 2016:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com New Study Presented at American Heart Association (AHA) Scientific Sessions
More informationA New Era for NOACs: What Does the Future Hold? CME
This article is a CME certified activity. To earn credit for this activity visit: http://www.medscape.org/viewarticle/884772 www.medscape.org A New Era for NOACs: What Does the Future Hold? CME Manesh
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationNews Release. For UK Media
News Release For UK Media Bayer plc 400 South Oak Way Reading RG2 6AD www.bayer.co.uk Bayer s Xarelto (rivaroxaban) in combination with single antiplatelet therapy receives positive CHMP opinion for treatment
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationΑντιθρομβωτική αγωγή σε ασθενείς με περιφερική αρτηριακή νόσο των κάτω άκρων
Αντιθρομβωτική αγωγή σε ασθενείς με περιφερική αρτηριακή νόσο των κάτω άκρων Μ. Ματσάγκας, MD, PhD, FEBVS Καθηγητής Αγγειοχειρουργικής Πανεπιστήμιο Θεσσαλίας Prevalence (millions) PAD Affects Millions
More informationRobert Storey. Sheffield, United Kingdom
Breakthrough Antiplatelets and Anticoagulants: Focus on brand new drugs Robert Storey Professor of Cardiology, Department of Cardiovascular Science, University of Sheffield and Academic Director and Honorary
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationAspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?
Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Ty J. Gluckman, MD, FACC, FAHA Medical Director, Center for Cardiovascular Analytics, Research and Data Science
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More information